Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

Nuvig Therapeutics Announces $161 Million Series B Financing, Plus Its Progression to Phase 2 with Novel, Second-Generation Immunomodulator

December 5, 2024 0

Nuvig Therapeutics in the NEWS Nuvig Therapeutics – a privately held biotech company, developing novel immunomodulatory therapeutics for patients with inflammatory autoimmune diseases, announced the closing of a $161 million Series B financing. The financing was co-led by Sanofi Ventures, Blue Owl Healthcare Opportunities (formerly Cowen Healthcare Investments), and Norwest Venture Partners, with participation from new investors, B Capital, Leaps by …

Iterum Therapeutics Receives US FDA Approval of ORLYNVAH™ for the...

The United States FDA Approved Astellas’ product VYLOY in Combination...

U.S. FDA Approves AbbVie’s VYALEV™ for Adults Living with Advanced...

Novo Nordisk Launches New Initiative To Prevent Childhood Obesity In...

The FDA Approved IntraBio Product AQNEURSA As the only treatment...

Jeune Aesthetics: Reversing the Biology of Aging Skin to Meet...

Galderma Receives U.S. FDA Approval for Nemluvio® for Adult Patients...

SCG Cell Therapy: FDA Approved IND Application of Product SCG142...

Mitsubishi Tanabe Pharma America Announced the Presentations of its ND0612...

AstraZeneca: The U.S. FDA Approved IMFINZI in Combination with Carboplatin...

Regeneron: Improved Hearing to Normal Levels in a Child with...

INmune Bio Inc. Update on Two Alzheimer Disease Patients Who...

Cerevel Therapeutics Announces Positive Results for Tavapadon in Phase 3...

Italfarmaco Received FDA Approval for Duvyzat™ for the Treatment of...

Abbott Laboratories Launches a New PROTALITY™ Brand to Maintain the...

Sanofi to Acquire Inhibrx, Inc.

Cognition Therapeutics CEO Issues Letter to Shareholders

For Migraine Patients and People Interested in New Migraine Results,...

Today at 2 PM, Akero Therapeutics Presented at the H.C....

Impacting News

Vertex Announces US FDA Approval of ALYFTREK™ Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis

December 23, 2024 0

Vertex Pharmaceuticals Vertex Pharmaceuticals (VRTX) announced a United States FDA has approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor), a once-daily …

Broadcom Inc’s Greatest Day

December 13, 2024 0

Broadcom Inc Q4 Financial Results for Broadcom Inc (AVGO) reported financial results for its fourth quarter …

Johnson & Johnson Product CARVYKTI® Improves Standard of Care Therapies for Relapsed or Refractory Multiple Myeloma

December 11, 2024 0

Johnson & Johnson On December 9, 2024, Johnson & Johnson (JNJ) announced new results from the Phase …

Intra-Cellular Therapies Submits Supplemental New Drug Application to the US FDA for CAPLYTA® Treatment of Major Depressive Disorder as Adjunctive Therapy

December 6, 2024 0

Intra-Cellular Therapies in the NEWS On December 3, 2024, Intra-Cellular Therapies (ITCI) announced the submission of …

Gilead and Tubulis Enter Exclusive Option and License Agreement to Develop Antibody Drug Conjugate That Targets Solid Tumors

December 4, 2024 0

Gilead Sciences and Tubulis Agreement Gilead Sciences (GILD) and Tubulis announced that they entered into an …

AstraZeneca Product Trugap+Abiraterone and Androgen Deprivation Therapy Improved Primary Endpoint of Radiographic PFS in PTEN-Deficient Metastatic Hormone-Sensitive Prostate Cancer

November 27, 2024 0

AstraZeneca in the NEWS AstraZeneca (AZN) Phase III trial CAPItello-281, which combines Truqap (capivasertib), abiraterone, and …

Trick or Trade

Revisiting Bluebird Bio Inc

December 18, 2024 0

Bluebird Bio Inc For investors who thought that bluebird bio Inc (BLUE) stock price jumped up …

InflaRx Reports Third Quarter 2024 Financial Results and Provides Business Update

November 12, 2024 0

InflaRX In March 2024, InflaRx Biopharmaceutical (IFRX) announced that it will pursue two initial immuno-dermatology indications …

Some Stories To Know About Vera and Viking Therapeutics

October 29, 2024 0

Vera Therapeutics and Viking Therapeutics Today, October 29, the market stocks’ prices moved south, including good …

Merck Discontinues Two Late-Stage Keytruda Trials and Other Important Information

August 29, 2024 0

Merck Updates Merck (MRK) provided updates on two Phase 3 trials, KEYNOTE-867 and KEYNOTE-630, stating that …

Serious is the Impact of Bad Circumstances

August 6, 2024 0

The Impact of Bad Circumstances Since early year 2024, in every Prohost Letter we have posted, …

BioStem Technologies’ Press Release and Conference Call Offered Encouraging News

April 2, 2024 0

BioStem Technologies Inc From Jason Matuszewski, CEO of BioStem Technologies (BSEM), who stated, “BioStem had an …

Today’s Highlights

Novo Nordisk: European Regulatory Authority Adopts Positive Opinion for an Update of Ozempic® Label to Reflect Risk Reduction of Kidney Disease-Related Events

December 12, 2024 0

Novo Nordisk Bagsværd, Denmark, 12 December 2024 – Novo Nordisk (NVO) announced that the European Medicines …

At ASH 2024, Gilead Sciences’ Kite’s Yescarta® Shows Its CAR T-Cell Therapy Uniquely Durable Response and Long-Term Survival After Five Years in Patients with Relapsed/Refractory Non-Hodgkin Lymphomas

December 10, 2024 0

Gilead Sciences Kite Pharma, a Gilead Sciences Company (GILD) announced results from a five-year follow-up analysis …

From ASH: Vertex Pharmaceuticals Presented Positive Durability Gene Editing CASGEVY for Severe Sickle Cell Disease and Transfusion-Dependent Beta-Thalassemia

December 9, 2024 0

Vertex Pharmaceuticals ASH Announcement Today, December 8, 2024, Vertex Pharmaceuticals (VRTX) announced longer-term data for CASGEVY™ …

Why Keros Therapeutics is Getting $200 Million Upfront Payment and Possibly Future Payments from Takeda That Could Exceed $1.1 Billion and More

December 3, 2024 0

Keros Therapeutics in the NEWS Today, December 3, 2024, Keros Therapeutics (KROS) announced an exclusive global …

PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington’s Disease Program

December 2, 2024 0

PTC Therapeutics in the NEWS Today, December 2, 2024, PTC Therapeutics (PTCT) announced the signing of …

Biogen and UCB Results: Phase 3 PHOENYCS GO Study Evaluating Dapirolizumab Pegol Demonstrated a Reduction in Systemic Lupus Erythematosus Disease Activity

November 19, 2024 0

Biogen & UCB Announcement Today, November 19, 2024, UCB (Euronext Brussels: (UCB) and Biogen (BIIB) presented …

Latest Articlesddd

Vertex Announces US FDA Approval of ALYFTREK™ Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis

December 23, 2024 0

Vertex Pharmaceuticals Vertex Pharmaceuticals (VRTX) announced a United States FDA has approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor), a once-daily …

Revisiting Bluebird Bio Inc

December 18, 2024 0

Bluebird Bio Inc For investors who thought that bluebird bio Inc (BLUE) stock price jumped up …

Broadcom Inc’s Greatest Day

December 13, 2024 0

Broadcom Inc Q4 Financial Results for Broadcom Inc (AVGO) reported financial results for its fourth quarter …

Novo Nordisk: European Regulatory Authority Adopts Positive Opinion for an Update of Ozempic® Label to Reflect Risk Reduction of Kidney Disease-Related Events

December 12, 2024 0

Novo Nordisk Bagsværd, Denmark, 12 December 2024 – Novo Nordisk (NVO) announced that the European Medicines …

Johnson & Johnson Product CARVYKTI® Improves Standard of Care Therapies for Relapsed or Refractory Multiple Myeloma

December 11, 2024 0

Johnson & Johnson On December 9, 2024, Johnson & Johnson (JNJ) announced new results from the Phase …

At ASH 2024, Gilead Sciences’ Kite’s Yescarta® Shows Its CAR T-Cell Therapy Uniquely Durable Response and Long-Term Survival After Five Years in Patients with Relapsed/Refractory Non-Hodgkin Lymphomas

December 10, 2024 0

Gilead Sciences Kite Pharma, a Gilead Sciences Company (GILD) announced results from a five-year follow-up analysis …

From ASH: Vertex Pharmaceuticals Presented Positive Durability Gene Editing CASGEVY for Severe Sickle Cell Disease and Transfusion-Dependent Beta-Thalassemia

December 9, 2024 0

Vertex Pharmaceuticals ASH Announcement Today, December 8, 2024, Vertex Pharmaceuticals (VRTX) announced longer-term data for CASGEVY™ …

Intra-Cellular Therapies Submits Supplemental New Drug Application to the US FDA for CAPLYTA® Treatment of Major Depressive Disorder as Adjunctive Therapy

December 6, 2024 0

Intra-Cellular Therapies in the NEWS On December 3, 2024, Intra-Cellular Therapies (ITCI) announced the submission of …

Nuvig Therapeutics Announces $161 Million Series B Financing, Plus Its Progression to Phase 2 with Novel, Second-Generation Immunomodulator

December 5, 2024 0

Nuvig Therapeutics in the NEWS Nuvig Therapeutics – a privately held biotech company, developing novel immunomodulatory therapeutics …

Gilead and Tubulis Enter Exclusive Option and License Agreement to Develop Antibody Drug Conjugate That Targets Solid Tumors

December 4, 2024 0

Gilead Sciences and Tubulis Agreement Gilead Sciences (GILD) and Tubulis announced that they entered into an …

Why Keros Therapeutics is Getting $200 Million Upfront Payment and Possibly Future Payments from Takeda That Could Exceed $1.1 Billion and More

December 3, 2024 0

Keros Therapeutics in the NEWS Today, December 3, 2024, Keros Therapeutics (KROS) announced an exclusive global …

PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington’s Disease Program

December 2, 2024 0

PTC Therapeutics in the NEWS Today, December 2, 2024, PTC Therapeutics (PTCT) announced the signing of …

AstraZeneca Product Trugap+Abiraterone and Androgen Deprivation Therapy Improved Primary Endpoint of Radiographic PFS in PTEN-Deficient Metastatic Hormone-Sensitive Prostate Cancer

November 27, 2024 0

AstraZeneca in the NEWS AstraZeneca (AZN) Phase III trial CAPItello-281, which combines Truqap (capivasertib), abiraterone, and …

The U.S. FDA Approved BridgeBio Pharma Product Attruby to Treat Adults with ATTR-CM to Reduce Cardiovascular Death and Hospitalization

November 25, 2024 0

BridgeBio Pharma in the NEWS BridgeBio Pharma (BBIO) focused on genetic diseases, announced that the United …

Viking Therapeutics Presented Results from Phase 2b VOYAGE Study of VK2809 in Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting® 2024

November 20, 2024 0

Viking Therapeutics Announcement On Nov. 19, 2024, Viking Therapeutics, Inc. (VKTX) announced that the final results …

Biogen and UCB Results: Phase 3 PHOENYCS GO Study Evaluating Dapirolizumab Pegol Demonstrated a Reduction in Systemic Lupus Erythematosus Disease Activity

November 19, 2024 0

Biogen & UCB Announcement Today, November 19, 2024, UCB (Euronext Brussels: (UCB) and Biogen (BIIB) presented …

Intellia Announces First Clinical Evidence from Phase 1 Study That an In Vivo CRISPR/Cas9-Based Gene Editing Therapy May Favorably Impact Disease Progression in Amyloidosis

November 19, 2024 0

Intellia Therapeutics Announcement On Nov. 16, 2024, Intellia Therapeutics (NTLA), a clinical-stage gene editing company focused …

Adaptimmune’s Lete-cel Achieves Primary Endpoint in Pivotal Trial Treating Advanced Sarcomas and Other Solid Cancers

November 15, 2024 0

Adaptimmune Therapeutics Announcement Today, November 13, 2024, Adaptimmune Therapeutics plc (ADAP), a company working to redefine …

PTC Therapeutics: U.S. FDA Approved a First-Time Gene Therapy Administered directly into the Brain to Treat Children and Adults

November 14, 2024 0

PTC Therapeutics Announcement Today, November 13, 2024, PTC Therapeutics, Inc. (PTCT) announced that the U.S. FDA accelerated …